Abstract
ObjectivesVaccines are one of the best interventions developed for eradicating COVID-19. This study aimed to provide evidence on Sinopharm COVID-19 vaccine side effects. MethodsA cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of the COVID-19 vaccine among individuals in the United Arab Emirates. Demographic data, vaccination and the response of people unwilling to take the COVID-19 vaccine were reported. ResultsSide effects post first vaccine dose of normal injection site pain, fatigue and headache were more common in participants aged ≤49 years versus >49 years, while pain at the vaccination site, fatigue, lethargy, headache and tenderness were the most common side effects post second dose in both groups. All side effects for both doses were more prevalent among participants aged ≤49 years. Side effects were more common in females compared with males for both doses. The most common reason for being unwilling to take the COVID-19 vaccine was that vaccines are not effective. ConclusionPost-vaccination side effects for the first and second doses were mild and predictable, and there were no hospitalization cases; this data will help reduce vaccine hesitancy.
Highlights
SARS-CoV-2, causing COVID-19 (Habas et al, 2020), has spread fast worldwide, resulting in various levels of illness
Persons who clicked on the link were directed to Google Forms and, to avoid issues of missing data, they had to respond to all the questions or were unable to proceed to the section of the survey
Most studies have assessed post-vaccination adverse reactions of the Pfizer–BioNTech, Moderna, and AstraZeneca vaccines (ElShitany et al, 2021, Chapin-Bardales et al, 2021, Kadali et al, 2021, Menni et al, 2021, Riad et al, 2021), while only 2 studies focus on the Sinopharm COVID-19 vaccine (Jayadevan et al, 2021, Hatmal et al, 2021)
Summary
SARS-CoV-2, causing COVID-19 (Habas et al, 2020), has spread fast worldwide, resulting in various levels of illness. On March 11, 2020, it was announced that SARS-CoV-2 is a worldwide pandemic, and it is with us to this day (Lai et al, 2020). Numerous therapeutic medications have been presented to resist COVID19, they remain supportive and require more randomized control studies to determine their efficacy and potency. Vaccines are one of the best interventions developed for eradicating COVID-19, saving millions of lives annually. The best option remains an effective, safe vaccine without severe adverse reactions. The lack of effective and approved COVID-19 treatment has triggered a vaccine development race, with 259 COVID19 vaccine projects underway from November 11, 2020. The rapid creation of vaccinations has increased the risk of vaccine safety issues (Haidere et al, 2021, Petousis-Harris, 2021)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
